妊娠期缺铁性贫血铁剂治疗的系统综述与网状Meta分析
该系统综述与网状Meta分析纳入53项随机试验(9145名妊娠期缺铁性贫血妇女),评估不同铁剂的有效性与安全性。
要点
- 静脉蔗糖铁较口服硫酸亚铁改善妊娠期缺铁性贫血妇女的血红蛋白和铁蛋白。
- 静脉羧基麦芽糖铁较口服硫酸亚铁改善血红蛋白,但证据来自单项试验。
- 口服铁剂最常见胃肠道不良反应, parenteral铁剂不良反应较少但可见局部疼痛、皮肤刺激及罕见过敏反应。
核心结论
- 妊娠期缺铁性贫血的铁剂疗效不一,静脉蔗糖铁有较好获益证据,静脉羧基麦芽糖铁有一定证据。
研究设计与样本
- 系统综述与网状Meta分析,检索2011年1月1日至2021年2月28日发表的随机试验,纳入妊娠期缺铁性贫血妇女,评估含至少60 mg元素铁的铁剂。
- 共纳入53项合格试验(9145名妇女),其中30项(15种干预,3243名妇女)纳入血红蛋白网状Meta分析,15项(9种干预,1396名妇女)纳入血清铁蛋白网状Meta分析。
主要发现
- 其他干预与硫酸亚铁比较的证据不足。
- 口服铁剂最常见不良反应为胃肠道反应(恶心、呕吐、排便改变), parenteral铁剂不良反应较少但包括局部疼痛、皮肤刺激及罕见过敏反应。
关键数值与推荐
- 纳入试验的铁剂需含至少60 mg元素铁,与另一种铁剂或非铁剂比较。
- 主要结局为基线至4周血红蛋白浓度变化,次要结局为4周血清铁蛋白变化及治疗相关严重和非严重不良事件。
临床怎么用
- 临床医生和政策制定者在给药前应考虑各铁剂的有效性,以确保有效治疗。
局限性
- 纳入网状Meta分析的30项血红蛋白试验中,22项 judged 为高或中等总体偏倚风险。
- 其他干预与硫酸亚铁比较的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous iron preparations are available for the treatment of iron deficiency anaemia in pregnancy. We aimed to provide a summary of the effectiveness and safety of iron preparations used in this setting. METHODS: We did a systematic review and network meta-analysis of randomised trials. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, trial registers, and grey literature for trials published in any language from Jan 1, 2011, to Feb 28, 2021. We included trials including pregnant women with iron deficiency anaemia and evaluating iron preparations, irrespective of administration route, with at least 60 mg of elemental iron, in comparison with another iron or non-iron preparation. Three authors independently selected studies, extracted data, and did a risk of bias assessment using the Cochrane tool (version 1.0). The primary outcome was the effectiveness of iron preparations, evaluated by changes in haemoglobin concentration at 4 weeks from baseline. The secondary outcomes were change in serum ferritin concentration at 4 weeks from baseline and treatment-related severe and non-severe adverse events. We did random-effects pairwise and network meta-analyses. Side-effects were reported descriptively for each trial. This study is registered with PROSPERO, CRD42018100822. FINDINGS: Among 3037 records screened, 128 full-text articles were further assessed for eligibility. Of the 53 eligible trials (reporting on 9145 women), 30 (15 interventions; 3243 women) contributed data to the network meta-analysis for haemoglobin and 15 (nine interventions; 1396 women) for serum ferritin. The risk of bias varied across the trials contributing to network meta-analysis, with 22 of 30 trials in the network meta-analysis for haemoglobin judged to have a high or medium global risk of bias. Compared with oral ferrous sulfate, intravenous iron sucrose improved both haemoglobin (mean difference 7·17 g/L, 95% CI 2·62-11·73; seven trials) and serum ferritin (mean difference 49·66 μg/L, 13·63-85·69; four trials), and intravenous ferric carboxymaltose improved haemoglobin (mean difference 8·52 g/L, 0·51-16·53; one trial). The evidence for other interventions compared with ferrous sulfate was insufficient. The most common side-effects with oral iron preparations were gastrointestinal effects (nausea, vomiting, and altered bowel movements). Side-effects were less common with parenteral iron preparations, although these included local pain, skin irratation, and, on rare occasions, allergic reactions. INTERPRETATION: Iron preparations for treatment of iron deficiency anaemia in pregnancy vary in effectiveness, with good evidence of benefit for intravenous iron sucrose and some evidence for intravenous ferric carboxymaltose. Clinicians and policy makers should consider the effectiveness of individual preparations before administration, to ensure effective treatment. FUNDING: None.
引用
- Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. Lancet Haematol. 2021. PMID: 34171281. doi:10.1016/S2352-3026(21)00137-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。